Results 301 to 310 of about 119,519 (336)

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment [PDF]

, 2008
Colagrande, M, Di Ianni,M, Lapecorella, M, Lucchesi,A, Mariani, G., NAPOLITANO, Mariasanta, Tabilio, A   +6 more
core  

Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012-2023. [PDF]

PLoS One
Zhong X, Luo J, Huang Y, Wang S, Huang Y.   +4 more
europepmc   +1 more source

Comparative Efficacy of Janus Kinase Inhibitors (JAKis) for Ulcerative Colitis in Japanese Regional Healthcare Facilities: A Real-World Database Study. [PDF]

Cureus
Itoi Y, Hashimoto Y, Masuo T, Masuda T, Marubashi K, Iwamoto A, Sekiguchi M, Takahashi K, Kimura Y, Hachisu Y, Tomaru S, Sato K, Tanaka H, Hosaka H, Kuribayashi S, Takeuchi Y, Uraoka T.   +16 more
europepmc   +1 more source

Incidental treatment of granulomatosis with polyangiitis with a Janus Kinase inhibitor in a patient undergoing alopecia treatment. [PDF]

JAAD Case Rep
Mendez D, Xiang L, Bergfeld W.
europepmc   +1 more source

Janus kinases and Src family kinases in the regulation of EGF induced vimentin expression in MDA-MB-468 breast cancer cells

, 2016
Teneale A. Stewart, Iman Azimi, Andrew J. Brooks, Erik W. Thompson, Sarah J. Roberts‐Thomson, Gregory R. Monteith   +5 more
openalex   +1 more source

Therapeutic Drug Monitoring for Precision Dosing of Janus Kinase Inhibitors: Protocol for a Prospective Observational Study.

JMIR Res Protoc
Tachet J, Decosterd LA, Guidi M, Girardin FR.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Janus-Kinase-Hemmer

Zeitschrift für Rheumatologie, 2012
Die Janus-Kinase-Inhibitoren stellen einen neuen therapeutischen Ansatz in der Behandlung der rheumatoiden Arthritis dar. In Phase-II- und -III-Studien zu Tofacitinib zeigte sich eine gute klinische Wirksamkeit mit einem ACR (American College of Rheumatology)-20-Ansprechen von > 50% sowohl fur die Mono- als auch die Kombinationstherapie mit Methotrexat.
E. Ostermeier, P. Roll, H.-P. Tony
openaire   +1 more source

Janus Kinase Mutations

Seminars in Oncology, 2009
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire   +2 more sources